Form 8-K Editas Medicine, Inc. For: Sep 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Editas Medicine (EDIT) PT Lowered to $46 at Stifel
September 30, 2021 8:30 AM EDTStifel analyst Dae Gon Ha lowered the price target on Editas Medicine (NASDAQ: EDIT) to $46.00 (from $65.00) while maintaining a Hold rating.
The analyst commented, "Having digested today's BRILLIANCE data (Leber's congenital amaurosis type 10 [LCA10]) - see our take HERE - we... More
Editas Medicine (EDIT) Efficacy Raises The Bigger Question - Stifel
September 29, 2021 1:39 PM EDTStifel analyst Dae Gon Ha weighed in on Editas Medicine (NASDAQ: EDIT) with shares under significant pressure (-20%) as investors digest the early Ph.1/2 BRILLIANCE data for EDIT-101 in Leber's congenital amaurosis type 10 (LCA10).
Ha said what they initially perceived... More
